STEAP1 and neoplasm: Bispecific T cell engagers (BiTEs), such as xaluritamig (AMG 509), simultaneously bind STEAP1 on cancer cells and CD3 on T cells, bridging them into close proximity, resulting in direct and potent activation of cytotoxic T cells to induce tumor cell killing [159].